Short Interest in Roche Holding AG (OTCMKTS:RHHBY) Declines By 40.6%

Roche Holding AG (OTCMKTS:RHHBY) was the target of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 2,782,461 shares, a decline of 40.6% from the January 29th total of 4,684,288 shares. Based on an average daily volume of 5,239,296 shares, the short-interest ratio is presently 0.5 days. Approximately 0.0% of the company’s stock are short sold. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 5,239,296 shares, the short-interest ratio is presently 0.5 days.

Roche Price Performance

OTCMKTS RHHBY opened at $59.55 on Friday. The business has a 50 day simple moving average of $55.49 and a 200 day simple moving average of $48.03. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. Roche has a 52-week low of $34.75 and a 52-week high of $60.85.

Wall Street Analysts Forecast Growth

RHHBY has been the topic of a number of research analyst reports. HSBC reaffirmed a “buy” rating and issued a $57.00 target price on shares of Roche in a report on Wednesday, December 10th. Morgan Stanley reaffirmed an “underweight” rating on shares of Roche in a report on Wednesday, February 4th. JPMorgan Chase & Co. raised shares of Roche from an “underweight” rating to a “neutral” rating in a report on Monday, December 8th. Citigroup assumed coverage on Roche in a report on Tuesday, January 27th. They set a “buy” rating for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Roche presently has a consensus rating of “Hold” and an average price target of $57.00.

Institutional Investors Weigh In On Roche

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sentinel Trust Co. LBA bought a new position in shares of Roche in the 3rd quarter valued at $878,000. Enterprise Financial Services Corp acquired a new stake in Roche during the 2nd quarter valued at approximately $208,000. North Star Asset Management Inc. raised its stake in Roche by 52.0% during the second quarter. North Star Asset Management Inc. now owns 26,305 shares of the company’s stock worth $1,072,000 after buying an additional 9,000 shares during the last quarter. FineMark National Bank & Trust bought a new position in shares of Roche in the 2nd quarter worth about $210,000. Finally, Vestmark Advisory Solutions Inc. bought a new stake in Roche in the third quarter worth approximately $597,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.